Precision Biosciences, Inc
precisionbiosciences.comWhat Do They Do?
Develops in vivo gene-editing therapies for people with genetic and infectious diseases, including chronic hepatitis B and Duchenne muscular dystrophy.
10-K for FY2025, filed Mar 12, 2026We are a clinical stage gene editing company dedicated to improving life by developing in vivo therapies for genetic and infectious…View ↗
PBGENE-HBV (Viral Elimination). PBGENE-HBV is our wholly owned in vivo gene editing program under investigation in a global first-in-human…View ↗
PBGENE-DMD (Excision). PBGENE-DMD is our development program for the treatment of Duchenne muscular dystrophy, or DMD. DMD is a genetic…View ↗
How Do They Make Money?
Collaborators pay under research, licensing, development and commercialization agreements through upfront and option fees, research funding, and milestone payments, with royalties tied to partner product sales. Precision earns fees as it provides licensed rights or research and development work, either at once or over time.
10-K for FY2025, filed Mar 12, 2026The Company’s revenues are generated primarily through collaborative research, license, development and commercialization agreements.View ↗
The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or…View ↗
Collaborative Arrangements – The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover…View ↗
Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the…View ↗
$34.3M
-
10-K for FY2025, filed Mar 12, 2026
$34.3M ↗
Who Are Their Customers?
Works with biotechnology and pharmaceutical companies through research, development and licensing agreements; partners evaluate or develop programs using Precision’s technology.
10-K for FY2025, filed Mar 12, 2026iECURE-OTC (Insertion). In partnership with iECURE, Inc. (“iECURE”), an ARCUS-mediated targeted gene insertion approach, ECUR-506, is being…View ↗
On January 7, 2024, we entered into a license agreement (the “TG License Agreement”) with TG Cell Therapy, Inc. (“TG Subsidiary”) and its…View ↗
On August 15, 2023, we entered into an asset purchase agreement (the “Imugene Purchase Agreement”) with Imugene Limited (“Imugene…View ↗
Novartis Pharma AGView ↗
Do Revenues Turn Into Profits?
No. It lost $45.7M in FY2025.
10-K for FY2025, filed Mar 12, 2026
−$52.1MView ↗
10-K for FY2025, filed Mar 12, 2026
−$45.7MView ↗
10-K for FY2025, filed Mar 12, 2026
−$65.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$32.7MView ↗
- ▲ +39% (Loss)
- vs −$23.5M in Q2 FY2025
-
Jul 27, 2026
Appoints Naresh Tanna as chief financial officer
Alex Kelly, the former CFO, became chief operating officer.
Sources
8-K, filed Jul 27, 2026
As part of these leadership changes, the Board appointed Alex Kelly, age 60, as Chief Operating Officer of the Company. Mr. Kelly…View ↗
Shrinking. Revenue fell 70% in 4 years, from $115.5M in FY2021 to $34.3M in FY2025, about 26% a year.
From CAR T to in vivo therapies
The older report presented ex vivo CAR T immunotherapies as a core development area alongside in vivo therapies. The latest report centers its strategy on in vivo therapies and describes azer-cel as a non-core ex vivo program being developed by licensees.
10-K for FY2022, filed Mar 9, 2023
Loading...
